Non-pharmacological management of gestational diabetes: The role of myo-inositol

J Complement Integr Med. 2019 Sep 17;17(2):/j/jcim.2020.17.issue-2/jcim-2019-0111/jcim-2019-0111.xml. doi: 10.1515/jcim-2019-0111.


Gestational diabetes mellitus (GDM) is the most common metabolic disorder occurring in pregnancy. GDM plays an important role in the current diabetes epidemic: exposure to a high glycemic environment during the early stages of development increases the risk of the fetus to develop type two diabetes mellitus (T2DM) in adult life. Various cardiometabolic risk factors are linked to GDM. A thorough knowledge of the risk factors and genes involved in the development of GDM, along with an understanding of the underlying pathophysiological mechanisms are crucial to properly identify patients at risk of developing this condition. There is growing evidence showing that myo-inositol, combined with an appropriate therapeutic regimen for GDM, can provide additional benefits to the patient. The aim of this review is to analyze the role of inositol isomers - especially myo-inositol (MYO-INS) - in the treatment of patients with GDM.

Keywords: diet; gestational diabetes; management; myo-inositol; pregnancy.

Publication types

  • Review

MeSH terms

  • Diabetes, Gestational / therapy*
  • Dietary Supplements*
  • Female
  • Fetal Development / drug effects*
  • Humans
  • Inositol / therapeutic use*
  • Pregnancy


  • Inositol